Quarterly report pursuant to Section 13 or 15(d)

Segment Information

 v2.3.0.11
Segment Information
 6 Months Ended
Jun. 30, 2011
SEGMENT INFORMATION [Abstract]  
Segment Reporting Disclosure [Text Block]
SEGMENT INFORMATION
The accounting policies of the segments are described in Note 1 of the Company’s audited consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2010.  Corporate charges are allocated to each of the reporting segments on the basis of total salary expense. Corporate charges include corporate headquarters costs and certain depreciation expenses. Certain corporate capital expenditures have not been allocated from the Sales Services segment to the other reporting segments since it is impracticable to do so.
On August 1, 2011 the Company announced the formation of its new business unit, Interpace BioPharma. Interpace BioPharma provides biopharmaceutical clients with full-service product commercialization solutions. These services include full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The initial revenue and costs associated with this unit are reflected in the Product Commercialization Services (PC Services) segment for both the three- and six-month periods ended June 30, 2011.

 
Sales
Services
 
Marketing
Services
 
Product Commercialization
 
Consolidated
Three months ended June 30, 2011:
 
 
 
 
 
 
 
Revenue
$
34,585

 
$
5,357

 
$
684

 
$
40,626

Operating income (loss)
$
438

 
$
(1,194
)
 
$
84

 
$
(672
)
Capital expenditures
$
111

 
$
10

 
$
—

 
$
121

Depreciation expense
$
370

 
$
93

 
$
—

 
$
463

 
 
 
 
 
 
 
 
Three months ended June 30, 2010:
 
 
 

 
 

 
 

Revenue
$
30,327

 
$
2,522

 
$
—

 
$
32,849

Operating loss
$
(590
)
 
$
(46
)
 
$
—

 
$
(636
)
Capital expenditures
$
875

 
$
—

 
$
—

 
$
875

Depreciation expense
$
241

 
$
14

 
$
—

 
$
255

 
 
 
 
 
 
 
 
Six months ended June 30, 2011:
 
 
 

 
 

 
 

Revenue
$
76,940

 
$
9,104

 
$
684

 
$
86,728

Operating income (loss)
$
2,037

 
$
(4,313
)
 
$
84

 
$
(2,192
)
Capital expenditures
$
119

 
$
130

 
$
—

 
$
249

Depreciation expense
$
736

 
$
194

 
$
—

 
$
930

 
 
 
 
 
 
 
 
Six months ended June 30, 2010:
 
 
 

 
 

 
 

Revenue
$
58,645

 
$
5,336

 
$
—

 
$
63,981

Operating loss
$
(1,876
)
 
$
(276
)
 
$
—

 
$
(2,152
)
Capital expenditures
$
1,024

 
$
—

 
$
—

 
$
1,024

Depreciation expense
$
478

 
$
28

 
$
—

 
$
506